Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Optipharm financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
₩5.1 K
2024-10-29
Market Capitalization
₩74.5 B
2024-10-29
Revenue
₩19.6 B
FY, 2024
CreditSafe Score
?
Score changed on Jun 10, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| KRW | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | 14.0B | 13.7B | 13.0B | 14.3B | 16.0B | 17.4B | 19.6B |
| Cost of goods sold | 4.9B | 6.2B | 2.4B | 19.0B | 8.4B | 12.1B | 13.5B |
| Gross profit | 9.1B | 7.7B | 11.6B | 8.9B | 8.9B | 5.3B | 6.2B |
| Gross profit margin, % | 56.1% | 88.7% | 62.2% | 55.4% | 30.3% | 31.3% | |
| Operating expense total | 9.0B | 7.8B | 13.2B | 10.9B | 9.9B | 6.4B | 6.9B |
| Depreciation and amortization | 702.9M | 856.7M | 984.4M | 1.1B | 1.1B | 1.4B | 1.6B |
| EBITDA | 123.6M | (135.3M) | (1.6B) | (2.1B) | (1.0B) | (1.2B) | (787.4M) |
| EBITDA margin, % | -1.0% | -12.2% | -14.4% | -6.5% | -6.7% | -4.0% | |
| EBIT | (580.2M) | (992.7M) | (2.6B) | (3.1B) | (2.2B) | (2.6B) | (2.4B) |
| EBIT margin, % | -7.3% | -19.8% | -22.0% | -13.5% | -15.1% | -12.3% | |
| Interest income | 144.3M | 501.5M | 325.4M | 234.2M | 464.4M | 665.4M | 598.8M |
| Interest expense | 168.9M | 158.6M | 108.3M | 173.8M | 353.5M | 477.3M | 544.3M |
| Pre tax profit | (604.5M) | (655.3M) | (2.4B) | (3.1B) | (2.0B) | (2.4B) | (2.4B) |
| Net Income | (604.5M) | (655.3M) | (2.4B) | (3.1B) | (2.0B) | (2.4B) | (2.4B) |